seratrodast
Sign in to saveSeratrodast (development name, AA-2414; marketed originally as Bronica) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997. As of 2017 seratrodast was marketed as Bronica in Japan, and as Changnuo, Mai Xu Jia, Quan Kang Nuo in China.
Chemical data
- Formula
- C22H26O4
- Molecular weight
- 354.4 g/mol
- IUPAC name
- 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
via PubChem
Research
105 papers- Seratrodast inhibits ferroptosis by suppressing lipid peroxidation.Cell death & disease · 2024
- Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation.Brain research · 2022
- [Thromboxane A2 antagonist--discovery of seratrodast].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan · 1999
- The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics.The Journal of asthma : official journal of the Association for the Care of Asthma · 2003
- Comparative Antioxidant Protection of Cochlear Hair Cells from Ototoxins.Molecules (Basel, Switzerland) · 2025
via PubMed
Article
10 sectionsContents
- Medical uses
- Contraindications and interactions
- Adverse effects
- Pharmacology
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Research
- References
Seratrodast (development name, AA-2414; marketed originally as Bronica) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997. As of 2017 seratrodast was marketed as Bronica in Japan, and as Changnuo, Mai Xu Jia, Quan Kang Nuo in China.
Unlike thromboxane synthase inhibitors such as ozagrel, seratrodast does not affect thrombus formation, time to occlusion and bleeding time. Seratrodast has no effect on prothrombin time and activated partial thromboplastin time, thus ruling out any action on blood coagulation cascade.